Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag in Pediatric Primary ITP (Switch from Eltrombopag)
NCT06281327Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avatrombopag in primary immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Mar 2024; status: recruiting.
02
Drugs
avatrombopag
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06281327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281327.